Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC
Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-pro...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/1/59 |
| _version_ | 1797520700126265344 |
|---|---|
| author | Camille Gauvin Vimal Krishnan Imane Kaci Danh Tran-Thanh Karine Bédard Roula Albadine Charles Leduc Louis Gaboury Normand Blais Mustapha Tehfe Bertrand Routy Marie Florescu |
| author_facet | Camille Gauvin Vimal Krishnan Imane Kaci Danh Tran-Thanh Karine Bédard Roula Albadine Charles Leduc Louis Gaboury Normand Blais Mustapha Tehfe Bertrand Routy Marie Florescu |
| author_sort | Camille Gauvin |
| collection | DOAJ |
| description | Background: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, <i>p</i> = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, <i>p</i> = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (<i>p</i> = 0.316), stage II (<i>p</i> = 0.024), and stage III (<i>p</i> = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting. |
| first_indexed | 2024-03-10T08:00:20Z |
| format | Article |
| id | doaj.art-b7d1f78fea3d40e9b7d385488bc5592c |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:00:20Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-b7d1f78fea3d40e9b7d385488bc5592c2023-11-22T11:30:53ZengMDPI AGCurrent Oncology1198-00521718-77292021-01-0128159360510.3390/curroncol28010059Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLCCamille Gauvin0Vimal Krishnan1Imane Kaci2Danh Tran-Thanh3Karine Bédard4Roula Albadine5Charles Leduc6Louis Gaboury7Normand Blais8Mustapha Tehfe9Bertrand Routy10Marie Florescu11Department of Internal Medicine, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology and Cell Biology, University of Montreal, Montreal, QC H3T 1J4, CanadaDepartment of Pathology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC H2X 0C1, CanadaInstitute for Research in Immunology and Cancer (IRIC), Montreal, QC H3T 1J4, CanadaCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, CanadaCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, CanadaCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, CanadaCentre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, CanadaBackground: Studies have shown that aggressive treatment of non-small cell lung cancer (NSCLC) with oligometastatic disease improves the overall survival (OS) compared to a palliative approach and some immunotherapy checkpoint inhibitors, such as anti-programmed cell death ligand 1 (PD-L1), anti-programmed cell death protein 1 (PD-1), and T-Lymphocyte-associated antigen 4 (CTLA-4) inhibitors are now part of the standard of care for advanced NSCLC. However, the prognostic impact of PD-L1 expression in the oligometastatic setting remains unknown. Methods: Patients with oligometastatic NSCLC were identified from the patient database of the Centre hospitalier de l’Université de Montréal (CHUM). “Oligometastatic disease” definition chosen is one synchronous metastasis based on the M1b staging of the eight IASLC (The International Association for the Study of Lung Cancer) Classification (within sixth months of diagnosis) or up to three cerebral metastasis based on the methodology of the previous major phase II randomized study of Gomez et al. We compared the OS between patients receiving aggressive treatment at both metastatic and primary sites (Group A) and patients receiving non-aggressive treatment (Group B). Subgroup analysis was performed using tumor PD-L1 expression. Results: Among 643 metastatic NSCLC patients, we identified 67 patients with oligometastasis (10%). Median follow-up was 13.3 months. Twenty-nine patients (43%) received radical treatment at metastatic and primary sites (Group A), and 38 patients (57%) received non-aggressive treatment (Group B). The median OS (mOS) of Group A was significantly longer than for Group B (26 months vs. 5 months, <i>p</i> = 0.0001). Median progression-free survival (mPFS) of Group A was superior than Group B (17.5 months vs. 3.4 months, <i>p</i> = 0.0001). This difference was still significant when controlled for primary tumor staging: stage I (<i>p</i> = 0.316), stage II (<i>p</i> = 0.024), and stage III (<i>p</i> = 0.001). In the cohort of patients who were not treated with PD-L1 inhibitors, PD-L1 expression negatively correlated with mOS. Conclusions: Aggressive treatments of oligometastatic NSCLC significantly improve mOS and mPFS compared to a more palliative approach. PD-L1 expression is a negative prognostic factor which suggests a possible role for immunotherapy in this setting.https://www.mdpi.com/1718-7729/28/1/59non-small cell lung canceroligometastaticoverall survivalPD-L1aggressive treatmentimmune checkpoint inhibitors |
| spellingShingle | Camille Gauvin Vimal Krishnan Imane Kaci Danh Tran-Thanh Karine Bédard Roula Albadine Charles Leduc Louis Gaboury Normand Blais Mustapha Tehfe Bertrand Routy Marie Florescu Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC Current Oncology non-small cell lung cancer oligometastatic overall survival PD-L1 aggressive treatment immune checkpoint inhibitors |
| title | Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC |
| title_full | Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC |
| title_fullStr | Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC |
| title_full_unstemmed | Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC |
| title_short | Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC |
| title_sort | survival impact of aggressive treatment and pd l1 expression in oligometastatic nsclc |
| topic | non-small cell lung cancer oligometastatic overall survival PD-L1 aggressive treatment immune checkpoint inhibitors |
| url | https://www.mdpi.com/1718-7729/28/1/59 |
| work_keys_str_mv | AT camillegauvin survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT vimalkrishnan survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT imanekaci survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT danhtranthanh survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT karinebedard survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT roulaalbadine survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT charlesleduc survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT louisgaboury survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT normandblais survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT mustaphatehfe survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT bertrandrouty survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc AT marieflorescu survivalimpactofaggressivetreatmentandpdl1expressioninoligometastaticnsclc |